VTRS · Viatris Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 4.4B | Twelve Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted EPS non-GAAP | $1.28 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted gross margin non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $4.13B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Net Earnings non-GAAP | $1.5B | Six Months Ended June 30, 2026 | — |
|
|
|||
| EBITDA non-GAAP | $1.28B | Six Months Ended June 30, 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $677.4M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Gross debt to adjusted EBITDA non-GAAP | 2.9 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTRS
this stock
Viatris Inc
|
$18.52B | +29.5% | -3.0% | — | 4.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTRS | +0.5% | -6.7% | +8.0% | -8.2% | +29.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +2.5% | -10.0% | -3.2% | -10.3% | +17.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.